NCT07287163

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 700 (estimated)
• Sponsor: Praxis Precision Medicines · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy

Detailed description

An open label extension clinical trial to assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures.

Conditions

• Epilepsy, Tonic-Clonic
• Focal Seizure
• Primary Generalized Seizure

Interventions

Type	Name	Description
DRUG	vormatrogine	Once daily oral

Timeline

• Start date: 2025-10-27
• Primary completion: 2028-05-31
• Completion: 2028-12-31
• First posted: 2025-12-17
• Last updated: 2025-12-17

Locations

20 sites across 5 countries: United States, Germany, Italy, Poland, Spain

Regulatory

• FDA-regulated drug study